肝硬化指数和高血压之间的非线性关系:NHANES 2017-2020年
Zihao Zhao1, Yuhong Ma, Weizhong Huangfu
1Department of General Practice, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Medicine
|November 8, 2025
概括
肝硬化指数 (HSI) 显示了与高血压风险的非线性联系,HSI 50.33.3左右的显著值效应. 这种关联在男性,老年人和患有心血管疾病的人群中更为强烈.
科学领域:
- 心脏病学 心脏病学
- 肝病学 肝病学是一种肝病学.
- 代谢综合征是代谢综合征的一种.
背景情况:
- 肝硬化指数 (HSI) 是肝硬化的一种非侵入性测量方法.
- 以前的研究表明,HSI和高血压之间存在联系.
- 这种关系的确切性质,包括潜在的非线性和修改因素,需要进一步调查.
研究的目的:
- 调查肝硬化指数 (HSI) 和高血压之间的非线性关系.
- 确定影响HSI与高血压相关的潜在修饰因素.
- 评估HSI作为代谢性高血压风险分层标记物的有用性.
主要方法:
- 来自2017-2020年NHANES数据集的7723名成年人的分析.
- 利用Pearson的奇方位和Student t测试进行跨HSI四分位数的基线特征比较.
- 采用多变量逻辑回归和值回归来分析HSI-高血压关联并确定转折点.
- 进行子组分析以评估效果修改.
主要成果:
- 鉴定出HSI和高血压之间存在显著的非线性关联,HSI = 50.33.3 的拐点.
- 高血压的风险在这个值以下显著增加 (OR=1.06),但在这个值以上没有任何关联 (OR=0.99).
- 在男性,老年人 (≥60岁) 和冠心病患者中观察到更强的关联,在后者群体中降低了值 (38.67).
结论:
- 肝硬化指数 (HSI) 显示了基于值的非线性关联与高血压.
- 高血压指标可以作为一种有价值的标志物,用于对代谢性高血压的风险分层.
- 根据性别,年龄和心血管疾病状况的效果修改突出了特定人群,其中HSI可能是一个更强大的指标.
相关概念视频
01:29Hypertension II: Pathophysiology
765
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
765
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
171
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
171
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
519
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
519
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
208
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
208
01:30Hypertension III: Clinical Manifestations and Diagnostic Studies
452
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
452
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
244
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
244